

PROVIDER QUICK POINTS

PROVIDER INFORMATION



December 9, 2020

Remdesivir (Veklury®) for Treatment of COVID-19

Blue Cross and Blue Shield of Minnesota and Blue Plus (Blue Cross) has received questions from providers about coverage of remdesivir (Veklury®) for treatment of coronavirus disease 2019 (COVID-19).

Blue Cross covers intravenous use of Veklury® according to its FDA-approved indication for treatment of adults and pediatric patients (12 years of age and older and weighing at least 40 kg) with COVID-19 requiring hospitalization. Where there are no available hospital beds, these healthcare settings may include “pop-up” hospitals and other facilities that have been converted to temporary hospital wards.

Due to insufficient evidence of safety and efficacy in patients with mild-to-moderate COVID-19 who do not require hospitalization, Blue Cross does not cover Veklury® for outpatient use. Other drug therapies have been authorized by the FDA for use in outpatient settings to treat patients with mild-to-moderate COVID-19 who are at high risk for developing severe disease, including bamlanivimab and combination treatment with casirivimab plus imdevimab.

Blue Cross will continue to monitor ongoing clinical studies evaluating Veklury® for off-label uses.

Products Impacted

This applies to all lines of business.

Questions?

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. Please contact provider services at **(651) 662-5200** or **1-800-262-0820** for all other questions.